Recent advances in the treatment of melanoma that involve immunotherapy and B-Raf inhibition have revolutionised cancer care for this disease. However, an un-met clinical need remains in B-Raf inhibitor resistant patients where first-generation B-Raf inhibitors provide only short-term disease control. | Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A C-Raf